News

A few years ago, Pfizer (NYSE: PFE) represented the ideal pharmaceutical stock investment. The company, as leader in the coronavirus vaccine and treatment market, offered a great deal of growth, and

AbbVie's (NYSE: ABBV) products are regularly used to help heal the sick, but the company's stock wasn't healthy for portfolios on Friday. The company published its latest quarterly earnings release

Shares of diabetes management equipment provider DexCom (NASDAQ: DXCM) had tumbled 17% by 11:15 a.m. ET on Friday, according to data provided by S&P Global Market Intelligence. The culprit was the

Shares in Avidity Biosciences (NASDAQ: RNA) soared by 42% in the week to Friday morning following the announcement of a unanimous deal for Avidity to be acquired by Novartis (NYSE: NVS) for $72 per

Fenimore Asset Management Inc. fully exited its position in Waters Corporation (NYSE:WAT), selling approximately $85.09 million in shares.

According to a Q3 2025 filing submitted to the U.S

Shares of DexCom (NASDAQ: DXCM), a medical device specialist, have lagged the broader market so far in 2025, down 11% year to date. The diabetes-focused healthcare company has faced several legal

There are plenty of attractive stocks on the market. Some, though, have significantly underperformed their growth potential this year, making them attractive at their current levels.

This list

Dyne Therapeutics (NASDAQ: DYN) had a Monday neither it nor its investors will ever forget. This wasn't of its own making, however, as a premium-priced buyout of a peer was attracting serious

A richly priced buyout seriously boosted the share price of biotech Avidity Biosciences (NASDAQ: RNA) as the stock trading week began. The company's equity rose by 42%, closing to land just below

The S&P 500 index was recently offering a tiny dividend yield of 1.2%. You can get as much as 7% from some of the world's largest drugmakers. But sometimes, a high yield is a sign of risk.

What does

One struggling pharma stock that could use a boost from a strong earnings report is Pfizer (NYSE: PFE). The company's valuation has plummeted in recent years as patent cliffs and question marks

If you are looking for a healthcare stock to add to your portfolio as October draws to a close, consider Intuitive Surgical (NASDAQ: ISRG), Merck (NYSE: MRK), and Johnson & Johnson (NYSE: JNJ). Each

Intuitive Surgical (NASDAQ: ISRG) has dominated the market for robotic-assisted surgery (RAS) devices for the better part of the last 20 years, with little competition to speak of in many of the

Being a big company comes with a lot of positives. But there are negatives, too. Some businesses end up imploding under their own weight because they face increased scrutiny and competition and

Vertex Pharmaceuticals (NASDAQ: VRTX) and Pfizer (NYSE: PFE) are both among the largest drugmakers in the world. The latter currently has the edge in this department, with a market cap of $141

A big dividend yield is nice to see, but it shouldn't be the only thing you look at when buying a stock. The actual business behind the yield is, in fact, more important. That's why you'll need to

On Friday, Pennsylvania-based Conestoga Capital Advisors disclosed selling 855,435 shares of Vertex (NASDAQ:VERX), an estimated $24.8 million transaction based on average prices in the third

UnitedHealth Group (NYSE: UNH) has been a top dividend stock to own for years. It has consistently provided investors with a reliable dividend, and it has made generous increases to the payout over

Dividend investors shouldn't be dissuaded from investing just because the S&P 500 (SNPINDEX: ^GSPC) has a miserly 1.2% yield. If you dig in a bit, you can find attractive dividend stocks, including

It isn't all that difficult to find high-yield dividend stocks -- say, those paying out at more than 4%. The real trick is finding a company that produces sufficient profitability and free cash flow

Dividend stocks are arguably worth a premium in the current environment. Between a prolonged government shutdown and President Donald Trump's trade wars, the economy and the market might be heading

Image source: Getty Images

LOS ANGELES CAPITAL MANAGEMENT LLC increased its position in AbbVie by 304,281 shares during Q3 2025, an estimated $61.96 million trade based on the average price for Q3

Verity & Verity, LLC disclosed in its Oct. 21, 2025, SEC filing a purchase of 907,855 shares of Pfizer Inc. valued at an estimated $22.41 million for the quarter ended Sep. 30, 2025.

According to a

Some might view UnitedHealth Group (NYSE: UNH) as a stock and a company in retreat. UnitedHealth's shares have plunged more than 40% below the high set in the fourth quarter of 2024. The health

Explore the exciting world of AbbVie (NYSE: ABBV) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends